{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:00:15Z","timestamp":1794916815751,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ICMR-JRF-2020-HRD (31) (135027)"],"award-info":[{"award-number":["ICMR-JRF-2020-HRD (31) (135027)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68272-5","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:54:22Z","timestamp":1768650862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape"],"prefix":"10.1038","volume":"17","author":[{"given":"Mohammad Sufyan","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnit","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reegina","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Divya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9624-027X","authenticated-orcid":false,"given":"Kashif","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruquaiya","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehak","family":"Pracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8473-0631","authenticated-orcid":false,"given":"Samreen","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prial","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Imam","family":"Faizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya Ramdas","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Nafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insha Mohi","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momina","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahoor Ahmad","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamenth Kumar","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulaganathan","family":"Mabalirajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-2353","authenticated-orcid":false,"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaprakash","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-1825","authenticated-orcid":false,"given":"Gaurav","family":"Kharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4562-566X","authenticated-orcid":false,"given":"Tanveer","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"68272_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68272_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra, A., Maiti, R., Mohan, P. & Gupta, P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur. J. Haematol. 112, 211\u2013222 (2024).","journal-title":"Eur. J. Haematol."},{"key":"68272_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"68272_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2018-99-115558","volume":"132","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. et al. Low CD19 antigen density diminishes efficacy of CD19 CAR T cells and can be overcome by rational redesign of CAR signaling domains. Blood 132, 963\u2013963 (2018).","journal-title":"Blood"},{"key":"68272_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01105-8","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial. Blood Cancer J. 14, 130 (2024).","journal-title":"Blood Cancer J."},{"key":"68272_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial. Leukemia 36, 189\u2013196 (2022).","journal-title":"Leukemia"},{"key":"68272_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba, S. et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat. Med. 27, 1797\u20131805 (2021).","journal-title":"Nat. Med."},{"key":"68272_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med."},{"key":"68272_CR9","doi-asserted-by":"crossref","unstructured":"Schneider, D. et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13. (2021).","DOI":"10.1126\/scitranslmed.abc6401"},{"key":"68272_CR10","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial. Blood Cancer J. 14. https:\/\/doi.org\/10.1038\/S41408-024-01105-8 (2024).","DOI":"10.1038\/S41408-024-01105-8"},{"key":"68272_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med 26, 1569\u20131575 (2020).","journal-title":"Nat. Med"},{"key":"68272_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","volume":"13","author":"SM Larson","year":"2023","unstructured":"Larson, S. M. et al. CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov. 13, 580\u2013597 (2023).","journal-title":"Cancer Discov."},{"key":"68272_CR13","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1182\/blood-2024-200899","volume":"144","author":"NN Shah","year":"2024","unstructured":"Shah, N. N. et al. Phase 1 Study of trispecific anti-CD20, anti-CD19, anti-CD22 (CAR20.19.22) T cells for relapsed, refractory B-cell malignancies. Blood 144, 3448\u20133448 (2024).","journal-title":"Blood"},{"key":"68272_CR14","doi-asserted-by":"publisher","unstructured":"Jayaraman, J. et al (2020). CAR-T design: elements and their synergistic function. EBioMedicine 58. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931 (2020).","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"68272_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Calderon, H., Posey, A. D. & Maus, M. V. Engineering and design of chimeric antigen receptors. Mol. Ther. Methods Clin. Dev. 12, 145\u2013156 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"68272_CR16","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjh.19348","volume":"204","author":"H Brillembourg","year":"2024","unstructured":"Brillembourg, H. et al. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br. J. Haematol. 204, 1649\u20131659 (2024).","journal-title":"Br. J. Haematol."},{"key":"68272_CR17","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood-2023-187663","volume":"142","author":"C Yin","year":"2023","unstructured":"Yin, C. et al. CAR T cell exhaustion but not ex vivo cytotoxicity is predictive of patient clinical response: an interim analysis of ACIT001\/EXC002, a phase Ib\/II trial of decentralized production of CAR T cells for treatment of relapsed\/refractory aggressive NHL and ALL. Blood 142, 2092\u20132092 (2023).","journal-title":"Blood"},{"key":"68272_CR18","doi-asserted-by":"publisher","unstructured":"Sheih, A. et al. (2020). Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11. https:\/\/doi.org\/10.1038\/S41467-019-13880-1","DOI":"10.1038\/S41467-019-13880-1"},{"key":"68272_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart, C. M. et al. IL-4 drives exhaustion of CD8\u2009+\u2009CART cells. Nat. Commun. 15, 7921 (2024).","journal-title":"Nat. Commun."},{"key":"68272_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao, Z. et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 14, 213 (2024).","journal-title":"Blood Cancer J."},{"key":"68272_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"68272_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"68272_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4143\/crt.2023.1205","volume":"56","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia: long-term follow-up. Cancer Res. Treat. 56, 945\u2013955 (2024).","journal-title":"Cancer Res. Treat."},{"key":"68272_CR24","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17\/ TH1 cells. Blood 124, 1070\u20131080 (2014).","journal-title":"Blood"},{"key":"68272_CR25","doi-asserted-by":"crossref","unstructured":"Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).","DOI":"10.1038\/s41467-023-40115-1"},{"key":"68272_CR26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025).","journal-title":"N. Engl. J. Med."},{"key":"68272_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"68272_CR28","doi-asserted-by":"publisher","unstructured":"Philipson, B.I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci. Signal. 13. https:\/\/doi.org\/10.1126\/SCISIGNAL.AAY8248 (2020).","DOI":"10.1126\/SCISIGNAL.AAY8248"},{"key":"68272_CR29","doi-asserted-by":"publisher","unstructured":"Derigs, P. et al. Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study. Leukemia 38. https:\/\/doi.org\/10.1038\/S41375-024-02392-7 (2024).","DOI":"10.1038\/S41375-024-02392-7"},{"key":"68272_CR30","doi-asserted-by":"publisher","unstructured":"Schubert, M.L. et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J. Hematol. Oncol. 16. https:\/\/doi.org\/10.1186\/S13045-023-01470-0 (2023).","DOI":"10.1186\/S13045-023-01470-0"},{"key":"68272_CR31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s42255-024-01034-7","volume":"6","author":"A Lakhani","year":"2024","unstructured":"Lakhani, A. et al. Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation. Nat. Metab. 6, 1143\u20131160 (2024).","journal-title":"Nat. Metab."},{"key":"68272_CR32","doi-asserted-by":"publisher","unstructured":"Akhtar et al. Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity. Cell Rep. Med. 6. https:\/\/doi.org\/10.1016\/J.XCRM.2025.102021 (2025).","DOI":"10.1016\/J.XCRM.2025.102021"},{"key":"68272_CR33","doi-asserted-by":"publisher","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6. https:\/\/doi.org\/10.1038\/S41392-021-00828-5 (2021).","DOI":"10.1038\/S41392-021-00828-5"},{"key":"68272_CR34","doi-asserted-by":"publisher","unstructured":"Jones, N. et al. Akt and STAT5 mediate na\u00efve human CD4\u2009+\u2009T-cell early metabolic response to TCR stimulation. Nat. Commun. 10. https:\/\/doi.org\/10.1038\/S41467-019-10023-4 (2019).","DOI":"10.1038\/S41467-019-10023-4"},{"key":"68272_CR35","doi-asserted-by":"publisher","unstructured":"Klebanoff, C.A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.95103 (2017).","DOI":"10.1172\/JCI.INSIGHT.95103"},{"key":"68272_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","volume":"12","author":"H Chi","year":"2012","unstructured":"Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325\u2013338 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"68272_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"68272_CR38","doi-asserted-by":"publisher","unstructured":"Mehra, V. et al. (2023). AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. J. Immunother. Cancer. 11. https:\/\/doi.org\/10.1136\/JITC-2023-007002","DOI":"10.1136\/JITC-2023-007002"},{"key":"68272_CR39","doi-asserted-by":"publisher","first-page":"1649993","DOI":"10.3389\/fgeed.2025.1649993","volume":"7","author":"A Ramdas Iyer","year":"2025","unstructured":"Ramdas Iyer, A. et al. CRISPR-mediated generation of a tumor-associated antigen-deficient Raji platform to investigate antigen loss in CAR-T cell therapy. Front. Genome Ed. 7, 1649993 (2025).","journal-title":"Front. Genome Ed."},{"key":"68272_CR40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"68272_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-022-00417-w","volume":"10","author":"M Mazinani","year":"2022","unstructured":"Mazinani, M. & Rahbarizadeh, F. CAR-T cell potency: from structural elements to vector backbone components. Biomark. Res. 10, 1\u201324 (2022).","journal-title":"Biomark. Res."},{"key":"68272_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu, S. et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 34, 386\u2013388 (2024).","journal-title":"Cell Res."},{"key":"68272_CR43","doi-asserted-by":"crossref","unstructured":"Barden, M. et al. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J. Immunother. Cancer 12. (2024).","DOI":"10.1136\/jitc-2024-010208"},{"key":"68272_CR44","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels, K. G. et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science 378, 1194\u20131200 (2022).","journal-title":"Science"},{"key":"68272_CR45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s43018-025-00927-0","volume":"6","author":"S Simon","year":"2025","unstructured":"Simon, S. et al. Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. Nat. Cancer 6, 647\u2013665 (2025).","journal-title":"Nat. Cancer"},{"key":"68272_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omto.2019.08.008","volume":"15","author":"A Krokhotin","year":"2019","unstructured":"Krokhotin, A. et al. Computationally guided design of single-chain variable fragment improves specificity of chimeric antigen receptors. Mol. Ther. Oncol. 15, 30\u201337 (2019).","journal-title":"Mol. Ther. Oncol."},{"key":"68272_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC-targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68272_CR48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","volume":"627","author":"O Hsia","year":"2024","unstructured":"Hsia, O. et al. Targeted protein degradation via intramolecular bivalent glues. Nature 627, 204\u2013211 (2024).","journal-title":"Nature"},{"key":"68272_CR49","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"68272_CR50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022\u20131033 (2020).","journal-title":"Nat. Immunol."},{"key":"68272_CR51","doi-asserted-by":"publisher","unstructured":"Chen, C. et al. Mitochondrial metabolic flexibility is critical for CD8\u2009+\u2009T cell antitumor immunity. Sci. Adv. 9. https:\/\/doi.org\/10.1126\/SCIADV.ADF9522 (2023).","DOI":"10.1126\/SCIADV.ADF9522"},{"key":"68272_CR52","doi-asserted-by":"publisher","unstructured":"Wu, H. et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat. Commun. 14. https:\/\/doi.org\/10.1038\/S41467-023-42634-3 (2023).","DOI":"10.1038\/S41467-023-42634-3"},{"key":"68272_CR53","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1021\/acssynbio.4c00109","volume":"13","author":"MS Kim","year":"2024","unstructured":"Kim, M. S. et al. Degron-based bioPROTACs for controlling signaling in CAR T cells. ACS Synth. Biol. 13, 2313\u20132327 (2024).","journal-title":"ACS Synth. Biol."},{"key":"68272_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s42255-021-00356-0","volume":"3","author":"K Han","year":"2021","unstructured":"Han, K. et al. Fasting-induced FOXO4 blunts human CD4\u2009+\u2009T helper cell responsiveness. Nat. Metab. 3, 318\u2013326 (2021).","journal-title":"Nat. Metab."},{"key":"68272_CR55","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.neuron.2018.08.017","volume":"99","author":"I Sch\u00e4ffner","year":"2018","unstructured":"Sch\u00e4ffner, I. et al. FoxO function is essential for maintenance of autophagic flux and neuronal morphogenesis in adult neurogenesis. Neuron 99, 1188\u20131203.e6 (2018).","journal-title":"Neuron"},{"key":"68272_CR56","doi-asserted-by":"publisher","unstructured":"Sullivan, J.A., Kim, E.H., Plisch, E.H., Peng, S.L., and Suresh, M. FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms. PLoS Pathog. 8. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1002533 (2012).","DOI":"10.1371\/JOURNAL.PPAT.1002533"},{"key":"68272_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"68272_CR58","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","volume":"103","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H. et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 103, e215\u2013e218 (2018).","journal-title":"Haematologica"},{"key":"68272_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68272_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68272_CR61","doi-asserted-by":"publisher","unstructured":"Dai, M.Y. et al. High-potency PD-1\/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells. Cell Death Dis. 13. https:\/\/doi.org\/10.1038\/S41419-022-05375-7 (20220.","DOI":"10.1038\/S41419-022-05375-7"},{"key":"68272_CR62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593\u2013598 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"68272_CR63","doi-asserted-by":"publisher","unstructured":"Lu, L. et al. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci. Adv. 10. https:\/\/doi.org\/10.1126\/SCIADV.ADJ6251 (2024).","DOI":"10.1126\/SCIADV.ADJ6251"},{"key":"68272_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero, J. A. et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat. Commun. 15, 8658 (2024).","journal-title":"Nat. Commun."},{"key":"68272_CR65","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","volume":"90","author":"E Mansfield","year":"1997","unstructured":"Mansfield, E., Amlot, P., Pastan, I. & FitzGerald, D. J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90, 2020\u20132026 (1997).","journal-title":"Blood"},{"key":"68272_CR66","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case, D. A. et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668\u20131688 (2005).","journal-title":"J. Comput. Chem."},{"key":"68272_CR67","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","volume":"63","author":"DA Case","year":"2023","unstructured":"Case, D. A. et al. AmberTools. J. Chem. Inf. Model 63, 6183\u20136191 (2023).","journal-title":"J. Chem. Inf. Model"},{"key":"68272_CR68","doi-asserted-by":"publisher","unstructured":"Prihoda, D. et al. BioPhi: a platform for antibody design, humanization and humanness evaluation based on natural antibody repertoires and deep learning. MAbs https:\/\/doi.org\/10.1101\/2021.08.08.455394 (2021).","DOI":"10.1101\/2021.08.08.455394"},{"key":"68272_CR69","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/protein\/gzq114","volume":"24","author":"D Bannister","year":"2011","unstructured":"Bannister, D. et al. Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid \u03b2-lactamase display. Protein Eng. Des. Sel. 24, 351\u2013360 (2011).","journal-title":"Protein Eng. Des. Sel."},{"key":"68272_CR70","doi-asserted-by":"publisher","unstructured":"Honorato, R. V. et al. The HADDOCK2.4 web server for integrative modeling of biomolecular complexes. Nat. Protoc. 19. https:\/\/doi.org\/10.1038\/S41596-024-01011-0 (2024).","DOI":"10.1038\/S41596-024-01011-0"},{"key":"68272_CR71","doi-asserted-by":"publisher","unstructured":"Azmi, I. et al. A saliva-based RNA extraction-free workflow integrated with Cas13a for SARS-CoV-2 detection. Front. Cell Infect. Microbiol. 11. https:\/\/doi.org\/10.3389\/FCIMB.2021.632646 (2021).","DOI":"10.3389\/FCIMB.2021.632646"},{"key":"68272_CR72","doi-asserted-by":"publisher","unstructured":"Faizan, M.I. et al. NSP4 and ORF9b of SARS-CoV-2 induce pro-inflammatory mitochondrial DNA release in inner membrane-derived vesicles. Cells 11. https:\/\/doi.org\/10.3390\/CELLS11192969 (2022).","DOI":"10.3390\/CELLS11192969"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68272-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:04:05Z","timestamp":1770815045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68272-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68272"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68272-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A. and Cellogen Therapeutics have filed a patent application related to the CAR T cell engineering strategies described in this study. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1549"}}